ФЕБУКСОСТАТ ДЛЯ ЛЕЧЕНИЯ ХРОНИЧЕСКОЙ ГИПЕРУРИКЕМИИ У ПАЦИЕНТОВ, СТРАДАЮЩИХ ПОДАГРОЙ

Фебуксостат – непуриновый, селективный ингибитор изоформ ксантиноксидоредуктазы, он является альтернативой ограниченному числу лекарственных препаратов для снижения уровня уратов, применяемых в последние десятилетия. Ингибирование ксантиноксидоредуктазы фебуксостатом более  мощно и эффективно, чем аллопуринолом, что подтверждается более частым достижением целевого уровня уратов в сыворотке крови, особенно у пациентов с высокой концентрацией уратов. В отличие от аллопуринола фармакокинетические свойства фебуксостата не зависят в значительной степени от почечного клиренса, что важно для пациентов с хроническими заболеваниями почек. В нескольких исследованиях  проводится дальнейшая оценка  безопасности  фебуксостата для  сердечно-сосудистой системы и его возможного позитивного воздействия на функции почек. Важно и то, что пациентам пожилого возраста не требуется коррекция дозы препарата.

1. Smith EUR, Diaz-Torne C, Perez-Ruiz F et al. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol, 2010, 24: 811-827.

2. Kuo CF, Grainge MJ, Zhang W et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol, 2015 Jul 7. doi: 10.1038/nrrheum.2015.91. [Epub ahead of print].

3. Hak AE, Curhan GC, Grodstein F et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis, 2010, 69: 1305-1309.

4. Smith E, Hoy D, Cross M et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis, 2014 Aug, 73(8): 1470-1476.

5. Vos T, Barber RM, Bell B et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015 Jun 7. pii: S0140-6736(15)60692-4.

6. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum, 2011, Oct, 63(10): 3136-3141.

7. Lawrence RC, Felson DT, Helmick CG et al, National Arthritis Data Wo Arthritis Rheum. 2008 Jan, 58(1): 26-35. Downloaded by [University of California, San Diego] at 06: 48 07 March 2016.

8. Kuo CF, Grainge MJ, Mallen C et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis, 2015 Apr, 74(4): 661-667.

9. Mikuls TR, Farrar JT, Bilker WB et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis, 2005 Feb, 64(2): 267-272.

10. Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother, 2011 Oct, 9(5): 271-285.

11. Winnard D, Wright C, Taylor WJ et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology, 2012, 51: 901-909.

12. Doherty M, Jansen TL, Nuki G et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis, 2012 Nov, 71(11): 1765-1770.

13. Singh JA, Hodges JS, Toscano JP et al. Quality of care for gout in the US needs improvement. Arthritis Rheum, 2007, 57: 822-829.

14. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther, 2015 Jan, 32(1): 31-41.

15. Edwards NL, Sundy JS, Forsythe A et al. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ, 2011, 14(1): 10-15.

16. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 2017, 76: 29-42.

17. Richette P, Perez-Ruiz F, Doherty M et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol, 2014 Nov, 10(11): 654-661.

18. Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol, 2014 May, 10(5): 271-283.

19. Zhang W, Doherty М, Bardin Т et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2006 Oct, 65(10): 1312-1324.

20. Khanna D, Khanna PP, Fitzgerald JD et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken), 2012 Oct, 64(10): 1447-1461.

21. Richette P, Bardin T. Gout. Lancet, 2010 Jan 23, 375(9711): 318-328.

22. Beara-Lasic L, Pillinger MH, Goldfarb DS. Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. Int J Nephrol Renovasc Dis, 2010, 3: 1-10.

23. Seth R, Kydd AS, Buchbinder R et al. Allopurinol for chronic gout. Cochrane Database Syst Rev, 2014 Oct 14, 10: CD006077.

24. Kydd AS, Seth R, Buchbinder R et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev, 2014 Nov 14, 11: CD010457.

25. Castrejon I, Toledano E, Rosario MP et al. Safety of allopurinol compared with other uratelowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatol Int, 2015 Jul, 35(7): 1127-1137.

26. Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol, 2015 Mar, 27(2): 164-169.

27. Perez-Ruiz F, Dalbeth N, Schlesinger N. Febuxostat, a novel drug for the treatment of hyperuricemia of gout. Future Rheumatol, 2008, 10, 3(5): 421-427.

28. Okamoto K, Eger BT, Nishino T et al. An extremely potent inhibitor of xanthine oxidoreductase. J Biol Chem, 2003, 278: 1848-1855.

29. The vision of Febuxostat. Teijin Pharma Limited. Project stories Vol. 01. Japan, 2013. Available at: http: //www.teijin-pharma.com/project/story01.html [Last accessed 23 August 2015].

30. Adenuric. European Medicines Agency. Human medicines. Authorisation details. United Kingdom, 2015. [Last accessed 19 August 2015].

31. Uloric. U. S. Food and Drug Administration. Drug approval package. United States, 2009. Available at: http: //www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000toc.cfm [Last accessed 19 August 2015].

32. The Pharmaceuticals and Medical Devices Agency annual report FY 2010. Japan, 2011: 147.

33. Uloric. Full prescribing information. U. S. Food and Drug Administration. United States, 2012: 2.

34. Perez-Ruiz F, Punzi L. Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations. Eur Rev Med Pharmacol Sci, 2015 May, 19(9): 1549-1552.

35. Adenuric. Public Summary Document. Pharmaceutical Benefits Advisory Committee. Australia, 2015. Page 1.

36. Japanese Society of Gout and Nucleic Acid Metabolism. Digest of Guideline for the Management of Hyperuricemia and Gout: second edition. Gout and Nucleic Acid Metabolism, 2010, 34(1): 109-144.

37. Zyloprim. U.S. Food and Drug Administration. Drugs@FDA. United States, 2015 [Last accessed 19 August 2015].

38. Takano Y, Hase-Aoki K, Horiuchi H et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005 Mar 4, 76(16): 1835-1847.

39. Okamoto K, Eger BT, Nishino T et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzymeinhibitor complex and mechanism of inhibition. J Biol Chem, 2003 Jan 17, 278(3): 1848-1855.

40. Osada Y, Tsuchimoto M, Fukushima H et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol, 1993 Sep 14, 241(2-3): 183-188.

41. Khosravan R, Grabowski BA, Wu JT et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet, 2006, 45(8): 821-841.

42. Khosravan R, Grabowski B, Wu JT et al. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol, 2008 Mar, 65(3): 355-363.

43. Zhang M, DI X, Xu L et al. Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals. Exp Ther Med, 2014 Feb, 7(2): 393-396.

44. Komoriya K, Hoshide S, Takeda K et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine Downloaded by [University of California, San Diego] at 06: 48 07 March 2016 dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids, 2004 Oct, 23(8-9): 1119-1122.

45. Khosravan R, Wu JT, Joseph-Ridge N et al. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol, 2006 Aug, 46(8): 855-866.

46. Mukoyoshi M, Nishimura S, Hoshide S et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica, 2008 May, 38(5): 496-510.

47. Grabowski B, Khosravan R, Wu JT et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a nonpurine selective inhibitor of xanthine oxidase. Br J Clin Pharmacol, 2010 Jul, 70(1): 57-64.

48. Hoshide S, Takahashi Y, Ishikawa T et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids, 2004 Oct, 23(8-9): 1117-1118.

49. Mayer MD, Khosravan R, Vernillet L et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther, 2005 Jan-Feb, 12(1): 22-34.

50. Khosravan R, Grabowski BA, Mayer MD et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol, 2006 Jan, 46(1): 88-102.

51. Khosravan R, Kukulka MJ, Wu JT et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol, 2008 Sep, 48(9): 1014-1024. Downloaded by [University of California, San Diego] at 06: 48 07 March 2016.

52. Doré M, Frenette AJ, Mansour AM et al. Febuxostat as a novel option to optimize thiopurines’ metabolism in patients with inadequate metabolite levels. Ann Pharmacother, 2014 May, 48(5): 648-651.

53. Febuxostat. ClincalTrials.gov. United States, 2015. Available at: https: //clinicaltrials.gov/ct2/results?term=febuxostat&pg=1 [Last accessed 23 August 2015].

54. Febuxostat. International Clinical Trials Registry Platform. World Health organization, 2015. Available at: http: //apps.who.int/trialsearch/default.aspx [Last accessed 25 August 2015].

55. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev, 2012 Nov 14, 11: CD008653.

56. Gray CL, Walters-Smith NE. Febuxostat for treatment of chronic gout. Am J Health Syst Pharm, 2011 Mar 1, 68(5): 389-398.

57. Becker MA, Schumacher HR, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med, 2005, 353: 2450–2461.

58. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight day, multicenter, phase II, randomized, doubleblind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum, 2005, 52: 916–923.

59. Schumacher HR, Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum, 2008, 59: 1540–1548. Downloaded by [University of California, San Diego] at 06: 48 07 March 2016.

60. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res, 2010, 12: R63.

61. Schumacher HR, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy study. Rheumatology, 2009, 48: 188–194.

62. Becker MA, Schumacher HR, MacDonald PA et al. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol, 2009, 36: 1273–1282.

63. Kamatani N, Fujimori S, Hada T et al. Placebocontrolled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. J Clin Rheumatol, 2011 Jun, 17(4 Suppl 2): S35-43.

64. Kamatani N, Fujimori S, Hada T et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purineselective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol, 2011 Jun, 17(4 Suppl 2): S44-49.

65. Kamatani N, Fujimori S, Hada T et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a nonpurineselective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol, 2011 Jun, 17(4 Suppl 2): S13-18.

66. Kamatani N, Fujimori S, Hada T et al. Placebocontrolled, double-blind study of the nonpurineselective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with Downloaded by [University of California, San Diego] at 06: 48 07 March 2016 hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol, 2011 Jun, 17(4 Suppl 2): S19-26.

67. Perez-Ruiz F, Chinchilla S, Atxotegi J et al. Rheumatology International, 2015, 35(11): 1857-1861.

68. MacDonald TM, Ford I, Nuki G et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open, 2014 Jul 10, 4(7): e005354.

69. White WB, Chohan S, Dabholkar A et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J, 2012 Jul, 164(1): 14-20.

70. Sánchez-Lozada LG, Tapia E, Soto V et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant, 2008 Apr, 23(4): 1179-1185.

71. Whelton A, Macdonald PA, Zhao L et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol, 2011 Jan, 17(1): 7-13.

72. Sircar D, Chatterjee S, Waikhom R et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis, 2015, DOI: 10.1053/j.ajkd.2015.05.017. Downloaded by [University of California, San Diego] at 06: 48 07 March 2016

73. Sofue T, Inui M, Hara T et al. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. Drug Des Deliv Ther, 2014 Feb 17, 8: 245-253.

74. Richette P, Frazier A, Bardin T. Impact of antiinflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout. Curr Opin Rheumatol, 2015 Mar, 27(2): 170-174.